|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
9.525 +0.115 (+1.222%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Turnover | 18,594,494 | 40.088% | 13,273,416 | 16,284,282 | 16,080,412 | 15,610,026 |
| Cost of Sales | (4,433,878) | -2.835% | (4,563,224) | (4,629,735) | (4,842,773) | (4,271,542) |
| Gross Profit | 14,160,616 | 62.575% | 8,710,192 | 11,654,547 | 11,237,639 | 11,338,484 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (3,924) | -69.269% | (12,769) | (51,669) | (18,503) | 823 | |
| Profit / (Loss) before Taxation | 7,529,123 | 141.499% | 3,117,667 | 3,801,130 | 3,681,554 | 3,719,460 | |
| Taxation | (1,068,947) | 96.636% | (543,617) | (749,664) | (623,514) | (692,377) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (365,964) | 1296.862% | (26,199) | (31,092) | (91,053) | (60,878) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 6,094,212 | 139.190% | 2,547,851 | 3,020,374 | 2,966,987 | 2,966,205 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (78,360) | 7.200% | (73,097) | (102,807) | (114,083) | (88,753) |
| Depreciation & Amortisation | 662,677 | -4.167% | 691,495 | 631,531 | 531,900 | 481,634 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 53.450 | 139.794% | 22.290 | 25.510 | 24.950 | 24.890 |
| DPS (cts) | 15.566 | -- | 12.780 | 14.648 | 12.858 | 8.715 |
| Dividend Payout Ratio (%) | 29.122% | -- | 57.335% | 57.423% | 51.536% | 35.015% |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 3.265 | -- | 2.887 | 2.930 | 2.673 | 2.350 |
| Remarks: | Real time quote last updated: 26/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 6,094,212 |
| %Change | 139.190% |
| EPS / (LPS) | RMB 0.535 |
| NBV Per Share (¥) | RMB 3.265 |